Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0PHYRI
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CD33-11A1-v1417 (C)-#39
|
|||||
| Synonyms |
CD33-11A1-v1417 (C)-#39
Click to Show/Hide
|
|||||
| Organization |
PFIZER INC.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.3
|
|||||
| Structure |
|
|||||
| Antibody Name |
anti-Her2 114 (H- (A114C)) and 183 (H- (kK183C)) mAb
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
CD33-11A1-v1417 (C)-#39 Payload
|
Payload Info | ||||
| Linker Name |
CD33-11A1-v1417 (C)-#39 Linker
|
Linker Info | ||||
| Conjugate Type |
Internal Cysteines
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 1.85 ng/mL | Positive CD33 expression (CD33+++/++) | ||
| Method Description |
CD33-target-expressing NB4 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 31 concentrations.
|
||||
| In Vitro Model | Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA | NB4 cells | CVCL_0005 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 3.43 ng/mL | Positive CD33 expression (CD33+++/++) | ||
| Method Description |
CD33-target-expressing HL60 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 31 concentrations.
|
||||
| In Vitro Model | Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation | HL60 cells | CVCL_0002 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 14.17 ng/mL | Positive CD33 expression (CD33+++/++) | ||
| Method Description |
CD33-target-expressing HEL92.1.7 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 31 concentrations.
|
||||
| In Vitro Model | Acute erythroid leukemia, Erythroleukemia | HEL92.1.7 cells | CVCL_2481 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 1000 ng/mL | Negative CD33 expression (CD33-) | ||
| Method Description |
CD33-non-expressing Raji cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 31 concentrations.
|
||||
| In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||
References